Osteocalcin immunolabeling during the alveolar healing process in ovariectomized rats treated with estrogen or raloxifene

Luvizuto, Eloá Rodrigues; Dias, Sheila Mônica Damásio; Queiroz, Thallita Pereira; Okamoto, Tetuo; Garcia, Idelmo Rangel; Okamoto, Roberta; Dornelles, Rita Cássia Menegati

doi:10.1016/j.bone.2009.12.016

Cited by 40 publications

(41 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both drugs were dissolved in an aqueous solution. 13,19 The drugs were administered for a total of 72 days of dosing, up to the end of the experiment (euthanasia).…”

Section: Bilateral Ovariectomy (Ovx)mentioning

confidence: 99%

See 1 more Smart Citation

Raloxifene enhances peri-implant bone healing in osteoporotic rats

Ramalho-Ferreira

Faverani

Prado

et al. 2015

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…Both drugs were dissolved in an aqueous solution. 13,19 The drugs were administered for a total of 72 days of dosing, up to the end of the experiment (euthanasia).…”

Section: Bilateral Ovariectomy (Ovx)mentioning

confidence: 99%

“…9 Several other drugs, including bisphosphonates 10,11 and selective oestrogen receptor modulators (SERMs), 12,13 are promising alternative therapies for the treatment of postmenopausal osteoporosis.…”

mentioning

confidence: 99%

Raloxifene enhances peri-implant bone healing in osteoporotic rats

Ramalho-Ferreira

Faverani

Prado

et al. 2015

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…Furthermore, Cantatore et al (2005) have reported that osteocalcin stimulates angiogenesis and may play a role in bone remodeling [29]. An immunohistochemistry study has suggested a role of OC during alveolar bone healing process [30]. However, it is not known how the bone protein OC appear in the CLP affected alveolar bone tissue.…”

Section: Int Conf Society Health Welfare 2014mentioning

confidence: 99%

Osteopontin, osteocalcin, and osteoprotegerin expression in human tissue affected by cleft lip and palate

Smane

Pilmane

2016

SHS Web Conf.

View full text Add to dashboard Cite

Abstract. Cleft lip and palate (CLP) is a common congenital anomaly with a complex etiology which has not been elucidated yet. This study investigated whether expression of osteopontin (OPN), osteoprotegerin (OPG), and osteocalcin (OC), which are essential for the normal craniofacial bone remodelling, is not regulated in children with CLP. Alveolar bone tissue samples were obtained from patients with complete bilateral (CB) CLP (n = 14) during corrective plastic surgery and unaffected control subjects (n = 9). OPN, OPG, and OC expression was assessed by immunohistochemistry, and data were analyzed with the Mann-Whitney test. OPN expression was observed only sporadically in the alveolar bone of 3 patients, in contrast to the control group (z = − 2.962; P < 0.003). The number of OPG-positive bone cells varied from occasional to moderate, in contrast to the control group (z = − 2.247; P = 0.025). OC-positive osteocytes were present in moderate to numerous numbers in both patients and controls, with no significant difference between them (z = − 1.356; P < 0.175). The prominent expression of OC characteristic for CBCLP affected hard tissue indicates a high potential of bone mineralization. Few OPG-positive osteocytes in the bone tissue implicate the disregulation of osteoclast differentiation, maturation, and activity, but few OPN-containing cells may prove the common disregulation of bone remodelling during cleft morphopathogenesis.

show abstract

“…25 Bone metabolism is regulated mainly by estrogen an essential hormone that acts on the cells involved in bone remodeling, such as osteocytes, osteoblasts and osteoclasts 26 which, in turn, can be influenced by systemic and local factors. 27 Estrogen has beneficial effects on skeletal tissue, minimizing bone resorption and acting directly or indirectly on cells of bone metabolism. Estradiol can also act in the expression of osteoprotegerin (OPG) and as receptor activator of nuclear factor kappa-β ligand (RANKL).…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the alveolar repair of rats treated with raloxifene is stabilized faster than in the group treated with estradiol, given that the serum levels of OPG increased while RANKL decreased. 27 In addition to OPG, RANKL also participates in osteoclastogenesis as a cytokine present in osteoblasts of which function is essentially related to bone metabolism. When RANKL binds to RANK, osteoclasts are activated, thereby increasing bone resorption.…”

mentioning

confidence: 99%

Influence of menopause on endodontic treatment

Gomes‐Filho¹,

Martins²,

Sivieri-Araújo³

et al. 2014

Dental Press Endod

View full text Add to dashboard Cite

Menopause is one of the physiological changes characterized by the end of menstrual and ovulatory cycles occuring in women in their fourth and fifth decade of life. Thereat, production of estrogen, an important hormone that acts in many physiological process of the individual such as the regulation of skeletal system, decreases. The decline in estrogen levels results in loss of bone mineral density, increased fracture risk, as well as bone diseases such as osteoporosis, a pathological process in which there is increased resorption of cavities that are not completely filled by newly formed bone. Furthermore, estrogen deficiency can cause many changes in an individual's oral health. In the presence of bacterial infection of pulp tissue, this deficiency can aggravate apical periodontitis. Several drugs have been studied as potential therapeutic agents to compensate for deficiency of estrogen. These drugs aim to reduce the likelihood of fractures and prevent bone loss as well as cardiovascular and mental disorders resulting from postmenopausal hormone disabilities. Raloxifene (RLX) is one of the most studied drugs therapies and proves to prevent bone loss. Even though raloxifene is indicated for and produces benefits to bone metabolism and maintenance of bone density, additional studies are warranted to further investigate the role of raloxifene in endodontic infection of osteopenic organisms.

show abstract

Osteocalcin immunolabeling during the alveolar healing process in ovariectomized rats treated with estrogen or raloxifene

Cited by 40 publications

References 51 publications

Raloxifene enhances peri-implant bone healing in osteoporotic rats

Raloxifene enhances peri-implant bone healing in osteoporotic rats

Osteopontin, osteocalcin, and osteoprotegerin expression in human tissue affected by cleft lip and palate

Influence of menopause on endodontic treatment

Contact Info

Product

Resources

About